Infection prevention and control in cystic fibrosis: One size fits all?
作者信息
Lands Larry C
机构信息
Pediatrics, McGill University, 1001 Boulevard Decarie, Room B.RC.7016, Montreal, Quebec H4A 3J1, Canada; Pediatric Respiratory Medicine, McGill University Health Centre, 1001 Boulevard Decarie, Room B.RC.7016, Montreal, Quebec H4A 3J1, Canada; Pediatric Cystic Fibrosis Clinic, McGill University Health Centre, 1001 Boulevard Decarie, Room B.RC.7016, Montreal, Quebec H4A 3J1, Canada.
出版信息
Paediatr Respir Rev. 2020 Nov;36:92-93. doi: 10.1016/j.prrv.2020.06.011. Epub 2020 Jun 20.
Abstract
摘要
相似文献
1
Infection prevention and control in cystic fibrosis: One size fits all?
Paediatr Respir Rev. 2020 Nov;36:92-93. doi: 10.1016/j.prrv.2020.06.011. Epub 2020 Jun 20.
2
Prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients.
Int J Med Microbiol. 2010 Dec;300(8):573-7. doi: 10.1016/j.ijmm.2010.08.010.
3
Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Cochrane Database Syst Rev. 2012 Nov 14;11:CD009528. doi: 10.1002/14651858.CD009528.pub2.
4
Pseudomonas aeruginosa in cystic fibrosis: pathogenesis and new treatments.
Br J Hosp Med (Lond). 2011 Nov;72(11):614-9. doi: 10.12968/hmed.2011.72.11.614.
5
The social network of cystic fibrosis centre care and shared Pseudomonas aeruginosa strain infection: a cross-sectional analysis.
Lancet Respir Med. 2015 Aug;3(8):640-50. doi: 10.1016/S2213-2600(15)00228-3. Epub 2015 Jul 22.
6
Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Cochrane Database Syst Rev. 2020 Jun 10;6(6):CD009528. doi: 10.1002/14651858.CD009528.pub5.
7
Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Cochrane Database Syst Rev. 2017 Oct 5;10(10):CD009528. doi: 10.1002/14651858.CD009528.pub4.
8
Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Cochrane Database Syst Rev. 2015 Mar 5(3):CD009528. doi: 10.1002/14651858.CD009528.pub3.
9
[Treatment of multiresistant Pseudomonas aeruginosa infection in cystic fibrosis: how to progress?].
Rev Mal Respir. 2010 May;27(5):411-3. doi: 10.1016/j.rmr.2010.04.003.
10
Pseudomonas aeruginosa infection in cystic fibrosis: biosynthesis of alginate as a virulence factor.
Antibiot Chemother (1971). 1991;44:63-7. doi: 10.1159/000420299.
本文引用的文献
1
Pro con debates in clinical medicine infection prevention and control in cystic fibrosis: One size fits all? The argument in favour.
Paediatr Respir Rev. 2020 Nov;36:97-99. doi: 10.1016/j.prrv.2020.06.008. Epub 2020 Jun 16.
2
Infection prevention and control in cystic fibrosis: One size fits all The argument against.
Paediatr Respir Rev. 2020 Nov;36:94-96. doi: 10.1016/j.prrv.2019.08.001. Epub 2019 Aug 21.
3
Infection prevention and control in cystic fibrosis: a systematic review of interventions.
Expert Rev Respir Med. 2019 May;13(5):425-434. doi: 10.1080/17476348.2019.1595594. Epub 2019 Mar 26.
4
Infection prevention and control guideline for cystic fibrosis: 2013 update.
Infect Control Hosp Epidemiol. 2014 Aug;35 Suppl 1:S1-S67. doi: 10.1086/676882. Epub 2014 Jul 1.
5
Transmission of communicable respiratory infections and facemasks.
J Multidiscip Healthc. 2008 May 1;1:17-27. doi: 10.2147/jmdh.s3019.
Zotero 插件